Apellis logo.jpg
Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
October 11, 2019 16:01 ET | Apellis Pharmaceuticals, Inc.
Company also provides an update on plans in nephrology CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage...
Apellis logo.jpg
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 26, 2019 08:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
September 16, 2019 17:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
September 11, 2019 16:38 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 28, 2019 08:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
July 31, 2019 17:00 ET | Apellis Pharmaceuticals, Inc.
Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019 Expects to Initiate Phase...
Apellis logo.jpg
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
July 22, 2019 07:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
July 18, 2019 07:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
June 27, 2019 07:39 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
June 15, 2019 10:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...